Parallel Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Parallel Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Buy	514 +210	+69%	+$49.1K	﹤0.01%	1503
2026 Q1	$69.5K	Buy	304 +148	+95%	+$33.2K	﹤0.01%	1802
2025 Q4	$33.3K	Hold	156	–	–	﹤0.01%	2055
2025 Q3	$31K	Hold	156	–	–	﹤0.01%	2036
2025 Q2	$26.9K	Hold	156	–	–	﹤0.01%	2053
2025 Q1	$24.3K	Hold	156	–	–	﹤0.01%	2035
2024 Q4	$21.5K	Hold	156	–	–	﹤0.01%	2118
2024 Q3	$23.3K	Hold	156	–	–	﹤0.01%	2011
2024 Q2	$21.3K	Hold	156	–	–	﹤0.01%	1945
2024 Q1	$23.6K	Hold	156	–	–	﹤0.01%	1893
2023 Q4	$19.6K	Buy	156 +118	+311%	+$11.8K	﹤0.01%	1958
2023 Q3	$3.56K	Buy	+38	New	+$3.56K	﹤0.01%	2619
2023 Q2	–	Sell	-74	Closed	-$7.93K	–	3362
2023 Q1	$7.93K	Hold	74	–	–	﹤0.01%	2230
2022 Q4	$9.04K	Sell	74 -1	-1%	-$116	﹤0.01%	2062
2022 Q3	$8K	Sell	75 -18	-19%	-$1.71K	﹤0.01%	2065
2022 Q2	$9K	Buy	93 +86	+1,229%	+$8.11K	﹤0.01%	2009
2022 Q1	$1K	Sell	7 -115	-94%	-$13.3K	﹤0.01%	2690
2021 Q4	$16K	Buy	122 +28	+30%	+$4.17K	﹤0.01%	1882
2021 Q3	$15K	Buy	+94	New	+$12.9K	﹤0.01%	1864

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Parallel Advisors's ASND Position: Q2 2026 in Review

Parallel Advisors increased its Ascendis Pharma A/S (ASND) stake by 69% in Q2 2026, buying an estimated $49.1K and bringing the position to 514 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

Parallel Advisors first reported a position in ASND in Q3 2021 and has held it in 19 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Parallel Advisors held 514 shares of Ascendis Pharma A/S worth $137K as of Q2 2026.
Parallel Advisors bought 210 Ascendis Pharma A/S shares in Q2 2026, an estimated $49.1K.
Ascendis Pharma A/S made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1503 holding.
Parallel Advisors first reported a position in Ascendis Pharma A/S in Q3 2021 and has held it in 19 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.